# Radiotherapy With or Without Concurrent Chemotherapy for Limited Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-02

> **NCT03308552** · PHASE3 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 164 (estimated)

## Conditions studied

- Esophageal Neoplasms

## Interventions

- **RADIATION:** SIB-IMRT
- **DRUG:** Paclitaxel
- **DRUG:** Platinum-Based Drug
- **DRUG:** Paclitaxel
- **DRUG:** Platinum-Based Drug

## Key facts

- **NCT ID:** NCT03308552
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-12-01
- **Primary completion:** 2020-08-30
- **Final completion:** 2021-08-30
- **Target enrollment:** 164 (ESTIMATED)
- **Last updated:** 2019-01-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03308552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03308552, "Radiotherapy With or Without Concurrent Chemotherapy for Limited Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-02". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03308552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*